Quarterly Canakinumab Reduces Risk for Gout Attacks

Share this content:
Quarterly Canakinumab Reduces Risk for Gout Attacks
Quarterly Canakinumab Reduces Risk for Gout Attacks

WEDNESDAY, Sept. 19, 2018 (HealthDay News) -- Quarterly canakinumab administration is associated with significantly reduced risk for gout attacks without any change in serum uric acid levels, according to a study published online Sept. 18 in the Annals of Internal Medicine.

Daniel H. Solomon, M.D., from Brigham and Women's Hospital in Boston, and colleagues evaluated the association between canakinumab, a monoclonal antibody targeting interleukin-1β; serum uric acid levels; and the incidence of gout attacks. Participants (10,059 with a prior myocardial infarction and a high-sensitivity C-reactive protein level ≥19.1 nmol/L) were included in a randomized trial of canakinumab (50 mg, 150 mg, or 300 mg) versus placebo, administered subcutaneously every three months.

The researchers found that for participants receiving placebo, incidence rates of gout attacks for serum uric acid concentrations of ≤404.5 µmol/L were 0.28 per 100 person-years, 1.36 per 100 person-years for concentrations 404.6 to 535.3 µmol/L, and 5.94 per 100 person-years for concentrations ≥535.4 µmol/L. For all baseline concentrations of serum uric acid, canakinumab did not affect serum uric acid levels over time, but significantly reduced rates of gout attacks: hazard ratios, 0.40 for concentrations of ≤404.5 µmol/L; 0.48 for those between 404.6 and 535.3 µmol/L; and 0.45 for concentrations ≥535.4 µmol/L.

"These data have relevance for the development of agents for gout that target the interleukin-1β pathway of innate immunity," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Novartis, which manufactures canakinumab and funded the study.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC: Progress in HIV Prevention Has Stalled in the United States

CDC: Progress in HIV Prevention Has Stalled in ...

Agency says effective HIV prevention, treatment not reaching those who could most benefit

AAAAI: Egg Oral Immunotherapy Shows Sustained Benefit in Children

AAAAI: Egg Oral Immunotherapy Shows Sustained Benefit in ...

All children with sustained unresponsiveness ingested concentrated and baked egg

Prenatal Vitamin Intake in Early Pregnancy May Cut Autism Risk

Prenatal Vitamin Intake in Early Pregnancy May Cut ...

ASD risk down for children whose mothers took prenatal vitamins during first month of pregnancy

is free, fast, and customized just for you!




Already a member?

Sign In Now »